MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

{"article_title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.","author":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P","journal_title":"Cancer","issn":"1097-0142","isbn":"","publication_date":"2020-10-01","volume":"126","issue":"19","first_page":"4423","page_count":"","accession_number":"32786044","doi":"","publisher":"Wiley","doctype":"Journal Article","subjects":"Mucositis etiology; Mucositis therapy; Neoplasms complications; Neoplasms therapy; Humans; Practice Guidelines as Topic","interest_area":["Oncology"],"abstract":"Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC\/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer. \u00a9 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=32786044","isPdfLink":true,"isSAML":false,"an":"32786044","number_other":"","type_pub":"","issn_electronic":"1097-0142","languages":"English","language":"eng","date_entry":"","date_update":"","titleSource":"Cancer [Cancer] 2020 Oct 01; Vol. 126 (19), pp. 4423-4431. Date of Electronic Publication: 2020 Jul 28.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2020-10-01","description":"Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO) Clinical Practice Guidelines for the management of mucositis.<br \/>Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.<br \/>Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions.<br \/>Conclusions: The updated MASCC\/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.<br \/> (© 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=32786044&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P","header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"32786044","RelevancyScore":"872","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"872.473937988281"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=32786044&authtype=shib&custid=ns346513&group=main&profile=eds","physicalDescription":{"Pagination":{"StartPage":"4423"}},"additionalInfo":{"Authored_By":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P","Corporate_Authors":"Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO)","Journal_Info":"Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE","Publication_Type":"Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Systematic Review","Published_Date":"2020-10-01","Source":"Cancer [Cancer] 2020 Oct 01; Vol. 126 (19), pp. 4423-4431. Date of Electronic Publication: 2020 Jul 28.","Languages":"English","Electronic_ISSN":"1097-0142","MeSH_Terms":"Mucositis\/*etiology , Mucositis\/*therapy , Neoplasms\/*complications , Neoplasms\/*therapy, Humans ; Practice Guidelines as Topic","Subjects":"Humans, Practice Guidelines as Topic, Mucositis etiology, Mucositis therapy, Neoplasms complications, Neoplasms therapy","Title_Abbreviations":"Cancer","Volume":"126"}}